Application of banana resistant starch-based bacteria encapsulation technique in cancer adjuvant therapy and dietary supplements development.

The role of gut microbiota both in human health and in disease has been the subject of intense investigation in last decades. Our team has established a banana resistant starch-based encapsulation platform, named EncapTa, for delivering large number of beneficial bacterial or bioactive materials successfully to the gastrointestinal tract. The EncapTa is a powerful technique for pharmaceuticals and supplements application.

1. The EncapTa enhance the viability of encapsulated bacteria during manufacturing processes.
2. Our unpublished experimental data indicated that EncapTa successfully protect encapsulated microbiota against low gastric pH and bile salt insults in vitro.
3. The EncapTa allow for oral delivery of small molecule, peptide, protein and microbiota as well.
4. EncapTa not only to improve the survival of encapsulated microbiota before colonizing the intestinal tract but also to optimize the gut commensal microbiota by resistant starch.
5. Materials used in establish EncapTa platform are completely natural.

The building block of EncapTa is resistant starch which was extracted from green banana. Resistant starch is composed of two type of polysaccharides: amylose and amylopectin. EncapTa has a broad spectrum of application in the field of oral “drug” delivery system especially for the acid-sensitive drug and the drug is absorbed mainly in colon.

 Look for: 

Strategic partner for the development of microbiota-targeted therapies, dietary supplement distributors, raw materials and semi-finished products supplier, OEM and ODM

 Booth No. N514